Abstract
The effects of hypoxia-reoxygenation on internal mammary (IMA) and radial (RA) arteries used for coronary artery bypass grafting (CABG) were examined to identify mechanisms regulating contractile function and differences that could contribute to vasospasm. Isolated endothelium-intact IMA and RA rings precontracted with KCl (30 mM) rapidly dilated to hypoxia (95% N2/5% CO2) with a greater relaxation in RA than IMA. Inhibitors of cyclooxygenase (10 μM indomethacin) and the thromboxane A2 (TxA)2 receptor [1 μM [1S-[1α,2α(Z),3α,4α]]-7-[3-[2-(phenylamino)carbonyl]hydrazine]methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid (SQ-29548)] potentiated the relaxation to hypoxia in IMA, but not RA, a response associated with increases in TxA2. Relaxation of IMA and RA to hypoxia appears to involve a calcium-reuptake mechanism inhibited by cyclopiazonic acid (0.2 mM), and it was not attenuated by a blocker of potassium channels (10 mM TEA). The recovery of force generation of IMA, but not RA, upon reoxygenation after 30 min of hypoxia was significantly reduced in the initial phase of reoxygenation by indomethacin and SQ-29548 and by endothelin receptor blocker BQ-123 [cyclo(l-Leu-d-Trp-d-Asp-l-Pro-d-Val)]. Thus, hypoxia relaxes IMA and RA by a postaglandin-independent mechanism potentially involving enhanced intracellular calcium reuptake. The prostaglandin-mediated alterations of responses to hypoxia-reoxygenation seen in IMA, but not in RA, may predispose IMA to vasospasm-related complications of CABG.
Footnotes
-
doi:10.1124/jpet.104.070995.
-
ABBREVIATIONS: IMA, internal mammary artery; CABG, coronary artery bypass grafting; RA, radial artery; NO, nitric oxide; PG, prostaglandin; TxA2, thromboxane A2; VSM, vascular smooth muscle; PKC, protein kinase C; SR, sarcoplasmic reticulum; PDBu, phorbol-12, 13-dibutyrate; COX, cyclooxygenase; PBS, phosphate-buffered saline; ET, endothelin; SQ-29548, [1S-[1α,2α(Z),3α,4α]]-7-[3-[2-(phenylamino)carbonyl]hydrazine] methyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid; BQ-123, cyclo(l-Leu-d-Trp-d-Asp-l-Pro-d-Val); U46619, 9, 11-dideoxy-9α, 11α-methanoepoxy prostaglandin F2α.
- Received May 4, 2004.
- Accepted June 30, 2004.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|